Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This price reduction will make broad molecular diagnostics accessible to more patients with cancer.
Robert Jan Lamers, Managing Director of Hartwig Medical Foundation:
“Every patient with cancer deserves access to the best possible diagnostics and treatment. By lowering the price, molecular diagnostics become available to more patients, supporting clinicians in selecting the bestt treatment options for their patients.”
The price reduction has been made possible by the implementation of the Illumina NovaSeq X-Plus sequencing platform, on which WGS has been validated for diagnostic use. Hartwig will also continue to contribute to the costs to further promote the use of WGS for patients.
OncoAct WGS can be used as reimbursed diagnostics for cancer of unknown primary (CUP/PTO), non-small cell lung cancer (NSCLC), and for determining responsiveness to NTRK-inhibitors, regardless of tumor type, subject to agreement with health insurers.
For AYA patients (Adolescents and Young Adults), OncoAct WGS remains free of charge for hospitals as part of the KWF-funded GENAYA-project. More information is available at GENAYA.nl.
Do you have any questions? Please consult with us.
You read an article in the category Whole genome sequencing. You may also be interested in Hartwig Medical Foundation, Lab process, Molecular diagnostics, OncoAct All newsAlso read
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
Collaboration for future-proof diagnostics and to accelerate research
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
Broader Testing in AYAs Helps
PhD candidates Jeffrey van Putten and Lina Lankhorst investigated whether AYAs (adolescents and young adults, diagnosed with cancer between the ages of …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.